Discordant performance of assays for free and total prostate-specific antigen in relation to the early detection of prostate cancer
- 1 October 2001
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 88 (6) , 545-550
- https://doi.org/10.1046/j.1464-410x.2001.02374.x
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- The clinical impact of different assays for prostate specific antigenBJU International, 2000
- New developments in the standardization of total prostate-specific antigenClinical Biochemistry, 1999
- On the Standardization of Total Prostate-Specific Antigen: an Exercise with Two Reference Preparationscclm, 1999
- Summary Report of the TD-3 Workshop: Characterization of 83 Antibodies against Prostate-Specific AntigenTumor Biology, 1999
- Reference material for PSA: the IFCC standardization studyClinical Biochemistry, 1998
- Prostate Cancer Detection in Men With Serum PSA Concentrations of 2.6 to 4.0 ng/mL and Benign Prostate ExaminationJAMA, 1997
- The European Randomized Study of Screening for Prostate Cancer (ERSPC)British Journal of Urology, 1997
- In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to α1-antichymotrypsin in blood samplesUrology, 1996
- Prostate-specific antigen: Problems in analysisEuropean Journal of Cancer and Clinical Oncology, 1991
- STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENTThe Lancet, 1986